The Ineffectiveness of CBD for Chronic Pain Management: Consumer Safety Implications

May 20, 2024

A new study published in The Journal of Pain sheds light on the ineffectiveness of cannabidiol (CBD) in
treating chronic pain. Analyzing 16 randomized double-blind trials encompassing over 900 participants,
the study revealed that CBD yielded no greater pain-relieving effect than a placebo.

Beyond efficacy, concerns have been raised regarding the safety of CBD, which is associated with
increased rates of serious adverse events. There is considerable variability in CBD content among
products, with some containing significantly more or less CBD than indicated on their labels.
Additionally, CBD products may contain other undisclosed compounds, some of which could pose risks
to consumers’ health. Beyond the absence of evidence supporting its efficacy in pain management, the
study underscores the persistent health concerns arising from the lack of purity and consistency in CBD
products.

In light of these findings, there is a pressing need for a new regulatory framework governing CBD
consumer products. Such measures are essential to ensure the purity, consistency, and accurate labeling
and marketing of CBD consumer products to protect consumers from potential harm.